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Several substances mark the course of lung cancer and may reliably help the clinician in decision-making. This is the ﬁrst clinical
study speciﬁcally designed to compare tissue polypeptide antigen and CA 125 tumour associated antigen. Three hundred and
eighty-four new lung cancer patients (309 males) were studied at their ﬁrst clinical presentation and then strictly followed-up.
Anthropometric, clinical and laboratory data – including tissue polypeptide antigen and CA 125 tumour associated antigen
serum levels – were prospectively recorded. A total of 1000 tissue polypeptide antigen and CA 125 tumour associated
antigen serum assays (384 pre-treatment and 616 posttreatment assays) were performed. Both tissue polypeptide antigen and
CA 125 tumour associated antigen correlated signiﬁcantly with the T, N and M stage descriptors at diagnosis (Rho: 0.200,
0.203, 0.263 and 0.181, 0.240, 0.276, respectively), and then with the objective response to treatment (Rho: 0.388 and 0.207,
respectively). A pleural neoplastic involvement was mainly associated to an increase of CA 125 tumour associated antigen
(Rho: 0.397). Both tissue polypeptide antigen and CA 125 tumour associated antigen were strongly predictive of the patients’
outcome, as assessed by the univariate analysis of survival (log-rank test: 37.24 and 29.01) and several Cox’ proportional
hazards regression models. The two marker tests are similarly helpful and appear complementary, given the low inter-marker
correlation and their independent prognostic capability.
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Tumour markers are not only of signiﬁcance to the researcher in
understanding tumour biology, but also to the clinician in treating
patients with cancer (Pamies and Crawford, 1996). In oncology
practice, tumour markers may be helpful in the diagnosis and in
the pathologic classiﬁcation. Plasma levels of serum tumour
markers may reﬂect both stage of disease and prognosis. When
measured serially after a diagnosis is established, they may aid in
assessing the response to treatment, in monitoring the spontaneous
course of the illness, and in surveillance for tumour recurrences
(Coombes and Powels, 1982).
Also in lung cancer, the expression of serum biomarkers is
various and abundant (Buccheri, 1999). Among them, markers
originating from the cytoskeleton are of conceptual and practical
interest (Buccheri and Ferrigno, 2001a). Tissue Polypeptide Anti-
gen (TPA) is identiﬁed as a degradation product of the
cytoskeleton, formed by the cytokeratins 8, 18 and 19 (Bjorklund,
1978). CA 125 tumour-associated antigen (CA125) is another
interesting lung tumour marker. It is a membrane glycoprotein
of the serous ovarian cancer cell line OVCA 433 recognised by
the monoclonal antibody OC125 (Bast et al, 1981). The use of
CA125 for diagnosis and follow-up of ovarian cancer was soon well
deﬁned (Bast and Klul, 1983). Currently, it is clear that CA125
might also be used as a marker of other cancers, including lung
cancer (Diez et al, 1991).
In this study, we describe the results of a new Cuneo Lung
Cancer Study Group’s (CuLCaSG) study aimed to compare
CA125 and TPA in each of their most important clinical applica-
tions. In particular, we compared the two marker tests in: (1)
Disease extent evaluation at diagnosis; (2) Treatment response
follow-up assessment; and (3) Prognostication. To our knowledge,
this is the ﬁrst report of this type.
PATIENTS AND METHODS
Patients’ database and study design
In 1982, a group of chest physicians, who later became known as
CuLCaSG, started working in the ﬁeld of lung cancer. The group
is still active at the Pulmonary Unit of the ‘S. Croce e Carle’ hospi-
tal, in the city of Cuneo, Piedmont, Italy. The hospital serves the
whole Cuneo Province as Third Referral Institution. Among the
prime actions of the CuLCaSG, a database for patients with carci-
noma of the lung, effective in January 1983, was created. All lung
cancer patients, referred to a physician of the group, were managed
uniformly and their clinical data recorded on computer.
All patients, seen in 1997 and afterwards, were included in this
study if they had a pathologic diagnosis of NSCLC (World Health
Organization, 1991). Based on our study requirements, all patients
had undergone each of the following: (1) Complete and accurate
assessment of the extent of disease; (2) Routine tumour marker
assays, including the determination of both pre-treatment and
post-treatment TPA and CA125 plasma levels; (3) A strict
follow-up and a yearly check of their status (for the few cases
who abandoned their follow-up programs). Follow-up re-evalua-
tions consisted of clinical, laboratory, and radiological
reassessments performed at 3-week intervals during chemotherapy,
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www.bjcancer.comand every 3–6 weeks in case of palliative radiotherapy, or no anti-
cancer treatment. Patients treated with radical surgery were sched-
uled for follow-up visits at longer intervals, ranging 3–6 months.
Based on our previous experience (Buccheri, 1999), tumour marker
assay was considered an essential part of the patients’ clinical
evaluation and no formal informed consent was required for this
study.
Survivals were recorded from the time of histological diagnosis
to death, or to the last clinical examination or telephone contact
with the patient himself, the family, the house doctor, or the muni-
cipal ofﬁce of the registry. Consequently, both the duration of
survival and the status of dead or alive at the closure of the study
(i.e., at the end of December 2001) was available for all patients. As
at December 2001, 176 patients (46%) were still alive, after a
median follow-up time of 23 weeks.
During the 5 year-period of study, 384 new eligible patients were
seen and included into the study. In all, 1000 twin TPA and CA125
plasma measurements (616 during or after treatment) were
obtained. The anthropometric and clinical characteristics of the
study cohort are shown in Table 1.
CA125 and TPA assays
Sera for CA125 and TPA were stored at 7208C, a temperature that
satisfactorily ensures the stability of blood specimens, and assayed
three times per week in the central laboratory of the ‘S. Croce and
Carle’ hospital. The laboratory is located in the ‘S. Croce’ building.
It receives blood samples from many medical and surgical wards,
including the lung unit of the ‘A. Carle’ building. Since we provide
no clinical information, biologists have no means of knowing even
the disease for which a particular test is required.
Plasma measurements were performed following the manufac-
turer’s instruction and using the reagents contained in the
commercial kits of AB Sangtec Medical Co., Bromma, Sweden
(TPA) and B-R-A-H-M-S Diagnostica GmbH, Berlin, Germany
(CA125). Reference values were up to 80 U l
71 (TPA) and
35 U ml
71 (CA125).
Other pre-treatment evaluations
All patients included in this report were studied with a computed
tomography (CT) of thorax, upper abdomen and brain. Mediast-
inal nodes were labelled as abnormal if they were 1.5 cm or
larger (smallest diameter). All CT scans were interpreted with no
restriction to the clinical information available at the time of the
exam. In addition to CT scanning, the baseline clinical evaluation
included physical examination, routine lab tests, bronchoscopy,
and functional respiratory tests. In nearly half of the sample, the
baseline work-up was supplemented by a technetium-99m methy-
lene diphosphonate bone scan. Other imaging tests (including X-
rays, CT and magnetic resonance imaging of the skeleton, ultraso-
nographic studies of the abdomen, and other organ-speciﬁc tests)
were optional and performed as clinically indicated. The pre-treat-
ment staging evaluation was pathological in 50 patients who
underwent surgical resection of the tumour (13% of the cohort).
All diagnostic and staging tests were obtained within a 2–3-week
period.
Data analysis and statistical considerations
Data were statistically analysed using the SPSS package for
Windows, Version 9.0 (SPSS Inc., Chicago, IL, USA). Non-para-
metric tests (Siegel, 1956) were used to test relationships and
differences among plasma levels of tumour markers or between
these factors and other variables. In particular, the Spearman rank
test, the Kruskall–Wallis test, and the median tests were used as
appropriate. Medians and ranges described continuous variables
because for many variables, including TPA and CA125, their distri-
bution was not Gaussian (Siegel, 1956).
Diagnostic capabilities were intended, for both TPA and CA125,
to show the presence (or absence) of a speciﬁc disease’s condition,
such as a metastatic spread or an objective response to treatment.
To assess diagnostic capabilities, we used the receiver-operating
characteristic (ROC) curves (McNeil et al, 1975), whose circum-
scribed areas (the area under the curve) give an estimate of the
diagnostic efﬁciency (Hanley and McNeil, 1982).
All the parameters assessed at diagnosis and listed in Table 1
were considered for survival analysis. Survival time was the depen-
dent variable. Survival curves were assessed according to the
Kaplan–Meier method (Kaplan and Meier, 1958), and plotted at
weekly intervals. Differences among curves were assessed according
to the log-rank test (Peto et al, 1977). To control for the effect of
potential confounders, a multivariate analysis, based on Cox’s
proportional hazards regression model (Cox, 1972), was
performed. For each variable included in the model the propor-
tional hazard assumption was tested graphically.
A probability (P) level 50.05 was considered statistically signif-
icant. All statistical tests were two-sided.
RESULTS
Inter-marker correlation and other clinical relationships
The plasmatic levels of the two markers, measured at the
patients’ ﬁrst clinical presentation, are plotted in Figure 1. In
the graph, each main cell type is graphically distinct with open
boxes of different grey tonality. The Spearman rank correlation
index was rather weak (Rho: 0.24), but still signiﬁcant given
the elevated number of measurements (P50.001). This correla-
tion indicates that there is a certain, though modest, overlap
in the expression of the two markers. As expected, the correla-
tion between CA125 and another more biologically similar
tumour marker, Carcinoembryonic Antigen (CEA), was remark-
ably higher (Rho=0.34). Both CA125 and TPA were
signiﬁcantly correlated with the serum levels of lactate dehydro-
genase, with the T, N, and M classiﬁcations, the presence of liver
metastasis, the scale of efﬁcacy in the adopted treatment, the
objective response to treatment, the posttreatment status of
disease and the performance status measured during the
follow-up (Table 2). In addition, TPA was associated or more
closely associated with other clinical factors, such as the amount
of weight loss, or with a few other lab tests, such as liver
enzymes and blood cell counts (Table 2). Typically, CA125
exhibited a strong association with the presence of pleural ﬂuid
(Rho=0.40). Exploiting such a characteristic, CA125 may be used
to predict a serous membrane involvement, normally a pleural
metastatic spread of the disease (Table 3 and Figure 2). Using
the CA125 normality reference, we could calculate for CA125 a
sensitivity rate of 77% and a speciﬁcity rate of 60% in the diag-
nosis of pleural neoplastic effusion.
Diagnosis of important clinical conditions
Table 3 shows the results of multiple ROC analyses intended to
assess the different diagnostic capability of the two markers under
evaluation. In particular, the capability to recognise three impor-
tant clinical conditions was considered. We analysed the
diagnosis of limited disease, as evidenced by: (1) a T1 category
of tumour involvement; (2) a N0 category of lymph node involve-
ment; and (3) a M0 category of metastatic disease. In addition, the
posttreatment diagnosis of objective response to treatment was
considered. All these analyses, except the CA125 ability to recognise
a T1 disease, resulted in high statistical signiﬁcance with a substan-
tially similar behaviour between the two tests (Table 3).
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Figures 3 and 4 show the Kaplan–Meier analyses of the survival,
based on the distribution of the plasma levels of CA125 (Figure
3) and TPA (Figure 4): categorisation was made using the median
as the cut-off value. Both graphs clearly show that a low marker
level was strongly associated with a more favourable outcome
(log-rank test: 29.01 and 37.24 for CA125 and TPA, respectively;
P always 50.001).
Table 4 summarises the best multivariate models obtained,
whether they included only tumour markers, or CA125 and/or
TPA along with a short list of standard prognostic factors (i.e.,
sex, age, performance status, and the TNM factors), or, ﬁnally,
whether they included all the variables listed in Table 1. In short,
while CEA possesses prognostic information that is contained with-
in either TPA or CA125, both these latter substances are
independent prognostic predictors. They remain independent
cofactors when standard prognostic factors are taken into account
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Table 1 Demographic and clinical characteristics of the study cohort
Characteristic No. Median Range Frequency
Age (yr) 384 67 39–88
Male sex (y/n) 384 309/75
Current smokers (y/n) 384 276/108
ECOG PS (0/1/2/3/4) 384 36/148/133/53/14
Tumour cell type (E/S/A/L/U) 384 134/40/120/35/55
Weight change in 6 months before diagnosis 381 76% 768% +25%
Serum blood tests:
Haemoglobin (g dl
71) 384 13.4 7.0–20.0
White blood cells (no. mm
73) 384 8460 2890–23000
Neutrophils (no. mm
73) 384 5624 832–18500
Lymphocytes (no. mm
73) 384 1669 490–5093
Platelets ((no. mm
73) 384 280000 72000–892000
SGOT (mg dl
71) 384 19 10–240
SGPT (mg dl
71) 384 21 3–202
Gamma glutamyl transpeptidase (mg dl
71) 381 35 9–1492
Alkaline phosphatase (mg dl
71) 382 89 40–2171
Lactate dehydrogenase (mg dl
71) 377 484 153–4985
Total serum protein content (g dl
71) 382 7.0 4.4–9.0
Bilirubin (mg dl
71) 382 0.6 0.1–4.4
Creatinine (mg dl
71) 384 0.9 0.5–4.8
Glucose (mg dl
71) 381 98 62–377
Na
+(mEq l
71) 380 141 115–147
Tumour markers:
CEA (ng ml
71) 384 3.6 1.5–7584
TPA (UL
71) 384 120 30–3500
CA125 (U ml
71) 384 36 2–5760
Tumour cavitation (y/n) 384 62/322
Pleural effusion (y/n) 384 119/265
TNM staging factors:
T factor (1/2/3/4) 384 50/143/57/134
N factor (0/1/2/3) 384 164/36/127/57
M factor (0/1) 384 231/153
Lung metastases (y/n) 384 69/315
Brain metastases (y/n) 384 63/321
Liver metastases (y/n) 384 45/339
Renal/suprarenal gland metastases (y/n) 384 22/362
Bone metastases (y/n) 384 38/346
Primary treatment (P/C/R/S) 384 142/179/13/50
Follow-up evaluations:
Followup visits 616 6 1–27
Objective response (CR/PR/MR/SD/PD) 616 152/167/64/93/140
ECOG PS (0/1/2/3/4) 616 85/295/182/45/9
TPA (UL
71) follow-up tests 616 80 22–4300
CA125 (U ml
71) follow-up tests 616 26 3–1560
Follow-up time (weeks) 384 23.00 1.3–195
Status (alive/dead) 384 176/208
ECOG PS=Eastern Cooperative Oncology Group performance status; yr=years; y=yes; n=no; no.=number. Tumour
cell type: E=epidermoid-squamous cell cancer; S=small cell cancer; A=adenocarcinoma; L=large cell anaplastic cancer;
U=undetermined or mixed cell type. Serum blood tests: SGOT=serum glutamic oxalacetic transaminase; SGPT=serum
glutamic pyruvic transaminase. Tumour markers: CEA=carcinoembryonic antigen; TPA=tissue polypeptide antigen;
CA125=CA125 tumour associated-antigen. Primary treatment: P=palliative and supportive care; C=chemotherapy;
R=radio-chemotherapy; S=surgical resection. Objective response category: CR=complete remission or post-opera-
tive disease free status; PR=partial remission; MR=minor regression; SD=stable disease; PD=progressive disease.
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ables are considered.
DISCUSSION
Nearly half a century ago, B Bjorklund (1953) was ﬁrst to propose
TPA as possible marker for epithelial tumours. He obtained the
antigen that called Tissue Polypeptide Antigen (TPA), mixing
different tumours and producing an immune serum against the
mixture. TPA is currently identiﬁed as a degradation product of
the cytoskeleton, formed by the cytokeratins 8, 18 and 19 (Bjork-
lund, 1978). It is expressed and immunohistochemically
detectable in the cytoplasm of epithelial tumour cells, including
bronchial cancer cells (Bjorklund, 1980).
Between 1986 and 1987, our group reported two clinical studies
which aimed to evaluate diverse serum tumour markers of lung
cancer (Buccheri et al, 1986, 1987). We found TPA the most useful
one, even more useful than CEA (Buccheri et al, 1987). We contin-
ued measuring TPA in all our patients with lung cancer and this
allowed us to re-evaluate and periodically conﬁrm earlier ﬁndings
(Buccheri and Ferrigno, 1988, 1992, 1995a,b; Ferrigno et al, 1989;
Buccheri et al, 1993). Recently, the clinical yield of TPA was deter-
mined either in the pre-treatment assessment of operability or in
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Figure 1 Scatter-plot showing pre-treatment levels of CA125 and TPA,
measured blindly of clinical information, in 384 new lung cancer patients
(Spearman Rho Correlation Coefﬁcient: 0.24).
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Figure 2 Receiver-operating characteristic (ROC) curves showing the
capability of CA125 to diagnose a cancerous pleural effusion (area under
the curve: 0.748, 95% conﬁdence interval: 0.695–0.801, P50.001).
Table 2 Bivariate correlations between TPA or CA125 and the other
clinical variables recorded on study
a
TPA (m l
71) CA125 (ng ml
71)
Age (yr) 0.140 0.009
Male sex (y/n) 70.124 0.044
Current smokers (y/n) 0.054 0.005
ECOG PS (0/1/2/3/4) 0.250 0.160
Tumour cell type (E/non E) 0.159 70.084
Tumour cell type (A/non A) 70.186 0.053
Weight change in the last 6 months 70.266 70.122
Serum blood tests:
Haemoglobin (g dl
71) 70.154 70.114
White blood cells (no. mm
73) 0.104 0.115
Neutrophils (no. mm
73) 0.129 0.141
Lymphocytes (no. mm
73) 70.131 70.125
Platelets (no. mm
73) 0.109 0.190
SGOT (mg dl
71) 0.206 0.069
SGPT (mg dl
71) 0.076 0.034
Gamma glutamyl transpeptidase (mg dl
71) 0.158 0.103
Alkaline phosphatase (mg dl
71) 0.158 0.148
Lactate dehydrogenase (mg dl
71) 0.327 0.239
Total serum protein content (g dl
71) 70.063 70.132
Bilirubin (mg dl
71) 0.015 70.057
Creatinine (mg dl
71) 0.066 70.062
Glucose (mg dl
71) 70.072 70.031
Na
+(mEq l
71) 70.054 70.075
Tumour markers:
CEA (ng ml
71) 0.199 0.343
TPA (UL
71) 1.000 0.235
CA125 (U ml
71) 0.235 1.000
Tumour cavitation (y/n) 0.123 0.089
Pleural effusion (y/n) 0.160 0.397
TNM staging factors:
T factor (1/2/3/4) 0.200 0.181
N factor (0/1/2/3) 0.203 0.240
M factor (0/1) 0.263 0.276
Lung metastases (y/n) 0.175 0.158
Brain metastases (y/n) 0.166 0.082
Liver metastases (y/n) 0.250 0.179
Renal/suprarenal gland metastases (y/n) 0.106 0.096
Bone metastases (y/n) 0.049 0.167
Primary treatment (P/C/R/S) 70.203 70.188
Follow-up evaluations:
Objective response (CR/PR/MR/SD/PD) 0.388 0.207
ECOG PS (0/1/2/3/4) 0.331 0.235
CA125 (U ml
71) follow-up tests 0.320 1.000
TPA (UL
71) follow-up tests 1.000 0.320
aValues are Spearman Rhos; correlations signiﬁcant at a P level 50.001 are marked in
bold. ECOG PS=Eastern Cooperative Oncology Group performance status;
yr=years; y=yes; n=no; no.=number. Tumour cell type: E=epidermoid-squa-
mous cell cancer; non E=non epidermoid-squamous cell cancer.
A=adenocarcinoma; non A=non adenocarcinoma. Serum blood tests:
SGOT=serum glutamic oxalacetic transaminase; SGPT=serum glutamic pyruvic trans-
aminase. Tumour markers: CEA=carcinoembryonic antigen; TPA=tissue
polypeptide antigen; CA125=CA125 tumor associated-antigen. Primary treat-
ment: P=palliative and supportive care; C=chemotherapy; R=radio-chemotherapy;
S=surgical resection. Objective response category: CR=complete remission or
post-operative disease free status; PR=partial remission; MR=minor regression;
SD=stable disease; PD=progressive disease.
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Figure 3 Kaplan–Meier’s estimates of the survival function based on the
50th percentile of the CA125 distribution (dashed line: values below the
median; values equal to or above the median: continuous line; log-rank test:
29.01, P50.001).
Table 3 Receiver-operating characteristic (ROC) analysis
95% conﬁdence interval
Pretreatment analysis (no. 384) AUC Lower limit Upper limit P- value
Diagnosis of T1
TPA (UL
71) 0.637 0.554 0.721 0.002
CA125 (U ml
71) 0.560 0.044 0.170 0.560
Diagnosis of N0
TPA (UL
71) 0.613 0.556 0.670 0.000
CA125 (U ml
71) 0.617 0.044 0.170 0.000
Diagnosis of M0
TPA (UL
71) 0.655 0.600 0.711 0.000
CA125 (U ml
71) 0.663 0.606 0.720 0.000
Diagnosis of pleural effusion
TPA (UL
71) 0.600 0.536 0.663 0.002
CA125 (U ml
71) 0.748 0.695 0.801 0.000 (Figure 2)
Posttreatment analysis (no.616)
Diagnosis of tumour response (CR or PR)
TPA (UL71) 0.682 0.640 0.724 0.000
CA125 (U ml
71) 0.623 0.579 0.667 0.000
AUC: area under the curve; CR: complete response or disease-free status; PR: partial response.
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Figure 4 Kaplan–Meier’s estimates of the survival function based on the
50th percentile of the TPA distribution (dashed line: values below the med-
ian; values equal to or above the median: continuous line; log-rank test:
37.24, P50.001).
Table 4 Cox’s regression analysis
a: summary of results
No. of Overall CA125
Variables explored valid Variables included (in order of entry) Chi-square P Wald statistic P
Tumour markers only
TPA and CA125 384 TPA, CA125 87.994 0.000 27.631 0.000
TPA, CA125 and CEA 384 CA125, TPA 86.565 0.000 22.161 0.000
Tumour markers plus standard PFs
b
CA 125 and PFs
b 381 ECOG-PS, M factor, CA125, WL, T factor 123.196 0.000 5.543 0.019
TPA, CA 125 and PFs
b 381 ECOG-PS, M factor, TPA, CA125, WL, N factor 142.792 0.000 4.889 0.027
TPA, CA 125, CEA and PFs
b 381 ECOG-PS, M factor, TPA, CA125, WL, N factor 142.792 0.000 4.889 0.027
All the recorded variables
34 pretreatment variables, as listed in Table 1 364 ECOG-PS, brain metastasis, main treatment
modality, tumour cavitation, CA125, N factor, TPA,
haemoglobin, T factor
172.761 0.000 9.653 0.002
ECOG-PS=Eastern Cooperative Oncology Group performance status; WL=per cent body weight loss in the prior 6 months; PFs=prognostic factors.
aStepwise forward regres-
sion (likelihood ratio), stratiﬁed by histology.
bSex, age, ECOG-PS, TNM factors.
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thresholds, surgical resectability (Buccheri and Ferrigno, 1995b,
2001b) and objective responses to treatment (Buccheri and
Ferrigno, 1995a) could be predicted with an accuracy similar to
that of computed tomography.
Evidence concerning the clinical value of CA125 is also remark-
able and, again, it is mainly due to one group of investigators
(Diez et al, 1991, 1994, 1996; Picardo et al, 1994). Like TPA,
the concentration of CA125 in the sera or in tumour cell cytosols
of lung cancer patients has been found increased in the most
advanced stages of disease (Diez et al, 1991; Kimura et al, 1990;
Picardo et al, 1994) and prognostically signiﬁcant (Diez et al,
1994, 1996).
The current study was designed to compare, in a comprehensive
manner and in a sufﬁciently large population, the above-discussed
two tumour markers, i.e. CA125 and TPA. To our knowledge,
there are no prior studies that have compared CA125 and TPA
in lung cancer.
Two prior investigations had reported the clinical yield of a
panel of lung tumour markers, including CA125 and the Cytoker-
atin 19-Fragments (Cyfra 21-1), an analogue of TPA (Buccheri and
Ferrigno, 2001a). To assess their diagnostic capability, 189 patients
with primary lung cancer and 50 healthy subjects were studied by
Molina et al (1994). Abnormal Cyfra 21-1 and CA125 values were
found in 53.6% and 39%, respectively, of the patients with active
cancer (Molina et al, 1994). More recently, Ando et al (2001)
investigated the same two tumour markers, along with other
marker substances, in 312 patients (200 patients with adenocarci-
noma; 112 patients with squamous cell carcinoma). In
adenocarcinoma patients, CEA showed the highest positivity rate
(46.5%), followed by CA125, whose positivity rate increased with
the stage of disease. In squamous cell carcinoma patients, the posi-
tivity rate of Cyfra 21-1 (48.2%) was the second highest, but
increased as the stage advanced.
The current study investigated the correlation between disease
extent and CA125, but also took into consideration two other
important clinical applications, i.e., the assessment of the response
to treatment – or the evaluation of the post-treatment status of
disease – and the prediction of outcome. Our results show that
both TPA and CA125 are similarly effective in each of the
above-mentioned applications with few, little differences. Both
TPA and CA125 correlated well with the extent of disease
(Rho=0.263 and 0.276, respectively), and the response to treat-
ment (Rho: 0.241 and 0.238). Univariate analyses of survival
showed that abnormally elevated values of both CA125 and
TPA were strongly associated with the worst prognosis
(P=0.001) and, ﬁnally, Cox’s multivariate models conﬁrmed their
prognostic signiﬁcance, demonstrating their independence from
any other possible survival determinant. The most important
difference between TPA and CA125, was the CA125 speciﬁc
response to the presence of pleural effusions. This is in accor-
dance with ﬁndings from another report (Kimura et al, 1993)
and may be explained by the fact that CA125 is an antigen that
normally exists in the ectodermal cells of peritoneum and pleura
(Kabawat et al, 1983).
CONCLUSIONS
For a biologic parameter to be used as a marker test, it is essential
that the assay is cheap, simple, objective, comparable, reproducible
and that the result is available in a short space of time to the
doctor. In our opinion, the serum quantiﬁcation of TPA and
CA125 clearly meets these requirements. We encourage clinicians
treating lung cancer patients to assay them before treatment (to
exploit their capability to give an insight into the severity of the
illness and into its possible outcome) and, serially, during and after
treatment (to help in deciding the status of the disease and its
response to the treatment). CEA appears less useful than CA125,
since its informative content appears, in some way, shaded by
CA125, and could be omitted.
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